2007
DOI: 10.1016/s1166-7087(07)92397-0
|View full text |Cite
|
Sign up to set email alerts
|

Epidémiologie et traitement des prostatites aiguës après biopsie prostatique

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(3 citation statements)
references
References 16 publications
0
3
0
Order By: Relevance
“…The clinical characteristics of acute prostatitis are poorly described in the published literature [ 2 , 3 ]. The majority of the literature focuses on post-biopsy prostatitis [ 4 , 5 , 6 ]. Flank pain is frequently described (from 5.1% in our study to 25%, two without any pyelonephritis), and prostatitis can be misdiagnosed initially as flank pain is interpreted as a clinical sign of pyelonephritis.…”
Section: Resultsmentioning
confidence: 99%
“…The clinical characteristics of acute prostatitis are poorly described in the published literature [ 2 , 3 ]. The majority of the literature focuses on post-biopsy prostatitis [ 4 , 5 , 6 ]. Flank pain is frequently described (from 5.1% in our study to 25%, two without any pyelonephritis), and prostatitis can be misdiagnosed initially as flank pain is interpreted as a clinical sign of pyelonephritis.…”
Section: Resultsmentioning
confidence: 99%
“…ABP associated with transrectal prostate biopsy is becoming more common with an incidence rate in the range 0.6%-2.1% (Stoica et al, 2007;Miura et al, 2008;Shigehara et al, 2008;Brede and Shoskes, 2011). Also, fluoroquinolone-resistant strains of E. coli were observed in most cases (Stoica et al, 2007;Miura et al, 2008;Shigehara et al, 2008).…”
Section: Classic Drug Choice For Complicated Abpmentioning
confidence: 99%
“…ABP associated with transrectal prostate biopsy is becoming more common with an incidence rate in the range 0.6%-2.1% (Stoica et al, 2007;Miura et al, 2008;Shigehara et al, 2008;Brede and Shoskes, 2011). Also, fluoroquinolone-resistant strains of E. coli were observed in most cases (Stoica et al, 2007;Miura et al, 2008;Shigehara et al, 2008). A retrospective study by Shigehara et al showed that a risk factor of fluoroquinoloneresistant E. coli may have been caused by the use of levofloxacin for prophylactic treatment, and to avoid this strain from generating, patients should receive levofloxacin for a short period before biopsy (Shigehara et al, 2008).…”
Section: Classic Drug Choice For Complicated Abpmentioning
confidence: 99%